A Phase III trial has shown T-DM1(ado-trastuzumab emtansine; Kadcyla, Genentech) is no better than a taxane for patients with HER2-positive, locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC). The study was presented at the Gastrointestinal Cancers Symposium (abstract 5).
The standard of care for first-line treatment ofHER2-positive metastatic GC/GEJC is trastuzumab (Herceptin, Genentech) with capecitabine-fluorouracil and cisplatin. There is no